Boston Scientific BSX has delivered an impressive return over the past year, with shares rallying 40.5%. The performance outpaced the industry’s 14.3% gain and the S&P 500 composite’s 12.5% rise.

PAHC stock is under investors' radar due to its booming animal health sales, new product lines and rising vaccine demand.